Squarepoint
TVRD

Squarepoint’s Tvardi Therapeutics TVRD Stock Holding History

Squarepoint’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,676
Closed -$104K – 5109
2026
Q1 		$104K Sell
32,676
-19,107
-37% -$74.9K ﹤0.01% 4062
2025
Q4 		$223K Buy
51,783
+43,619
+534% +$391K ﹤0.01% 3798
2025
Q3 		$318K Buy
+8,164
New +$232K ﹤0.01% 3618
2024
Q1 		– Sell
-1,072
Closed -$28.7K – 4724
2023
Q4 		$28.7K Buy
+1,072
New +$44.4K ﹤0.01% 3894
2023
Q2 		– Sell
-5,439
Closed -$961K – 4107
2023
Q1 		$961K Buy
+5,439
New +$1.82M ﹤0.01% 1923
2022
Q3 		– Sell
-728
Closed -$239K – 3543
2022
Q2 		$239K Buy
+728
New +$255K ﹤0.01% 2381
2022
Q1 		– Sell
-401
Closed -$176K – 3651
2021
Q4 		$176K Buy
401
+40
+11% +$20.1K ﹤0.01% 2758
2021
Q3 		$201K Buy
+361
New +$181K ﹤0.01% 2487
2021
Q2 		– Sell
-296
Closed -$232K – 3782
2021
Q1 		$232K Buy
+296
New +$203K ﹤0.01% 2607
2020
Q4 		– Sell
-868
Closed -$397K – 3326
2020
Q3 		$397K Buy
+868
New +$504K 0.01% 1610
2020
Q2 		– Sell
-311
Closed -$148K – 2567
2020
Q1 		$148K Sell
311
-863
-74% -$469K ﹤0.01% 1559
2019
Q4 		$681K Buy
1,174
+885
+306% +$621K ﹤0.01% 1577
2019
Q3 		$190K Buy
+289
New +$240K ﹤0.01% 2097
2018
Q4 		– Sell
-272
Closed -$235K – 2292
2018
Q3 		$235K Buy
+272
New +$196K ﹤0.01% 1677
2018
Q1 		– Sell
-2,460
Closed -$1.08M – 2223
2017
Q4 		$1.08M Buy
+2,460
New +$1.12M 0.02% 792
2017
Q1 		– Sell
-2,452
Closed -$820K – 1958
2016
Q4 		$820K Buy
+2,452
New +$787K 0.03% 583

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Squarepoint's TVRD Position: Q2 2026 in Review

Squarepoint sold out of Tvardi Therapeutics (TVRD) in Q2 2026, closing a stake of 32,676 shares — an estimated $104K sold.

Squarepoint first reported a position in TVRD in Q4 2016 and held it in 16 quarters. The position peaked at $1.08M in Q4 2017. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Squarepoint reported no remaining Tvardi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 32,676 Tvardi Therapeutics shares in Q2 2026, an estimated $104K.
  • Squarepoint first reported a position in Tvardi Therapeutics in Q4 2016 and held it in 16 quarters.
  • Squarepoint's Tvardi Therapeutics position peaked at $1.08M in Q4 2017.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.